> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Expanded Indication for Abbott Heart Catheter
- URL: https://www.fdaweb.com/expanded-indication-for-abbott-heart-catheter/
- Published: 2023-02-02T12:00:00.000Z
- Updated: 2026-09-14T18:14:15.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5153691

FDA has approved an expanded indication for Abbott’s FlexAbility sensor-enabled ablation catheter, a flexible tip catheter that the company says helps doctors identify abnormal signals and apply therapy to treat ventricular tachycardia (VT) with non-ischemic cardiomyopathy (NICM). A company [statement](https://abbott.mediaroom.com/2023-02-02-Abbott-Announces-US-and-European-Approvals-for-New-Technologies-to-Support-Effective-Treatment-for-Abnormal-Heart-Rhythms?ref=fdaweb.com) says its LESS-VT study was the first FDA-approved premarket trial to study the safety and effectiveness of ablation to treat VT with NICM origin.

Once treated with the FlexAbility catheter, the company says, 80% of study patients were free from VT for at least six months post-procedure. It says the data also showed significant improvements in patients’ mental and physical quality-of-life measures.

The company says the catheter has been intended for use with a compatible irrigation pump and a compatible RF cardiac ablation generator. It is intended for creating endocardial lesions during cardiac ablation procedures to treat typical atrial flutter.